Compounds for inhibiting agc kinase and pharmaceutical compositions comprising the same

Abstract

A compound of formula (I) or a pharmaceutically acceptable salt thereof is provided. In formula (I), Ar is indazole, 5-isoquinoline, 6-isoquinoline, or their N-oxide. X is —C(═Z)—, wherein Z is N—CN, NH, NR, NCOR, NCONRR, NCO-aryl, S, or O. Y and J are independently H, alkyl, aryl, aminoalkyl, —NH, —CN, —OH, —O-alkyl, —O-aryl, —COOH, —COOR, —CONHR, —CONHCH-aryl, —CONRCH-aryl, —NHCOR, halogen, halogened alkyl, -alkyl-OR, -alkyl-ONO, alkyl-ONO, —OCOOR, —O(C═O)-aryl, —CHROH, —CHOH, —CHO(C═O)-aryl, —CHO(C═O)—R, —CHRO(C═O)-aryl, —CHRO(C═O)—R, unsaturated carboxylic ester, substituted alkynyl, —NHSOR, —SOR, —SONHR, or —SONRR, or Y and J bond together to form a carbocylic or aromatic ring, wherein Rand Rare independently H, substituted C1-C6 alkyl, substituted aryl, cycloalkyl, alkylaryl, -alkyl-NRR, —S(O)-(alkyl-NRR). R, Rand Rare H, C1-C6 alkyl, cycloalkyl, aryl, alkylaryl, alkylheteroaryl, alkylheterocycle, wherein any one thereof is optionally substituted with one or more of OH, NO, or NRR.